Search Results

You are looking at 71 - 80 of 823 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho

patients with systemic cancer will develop brain metastases. 3 Principles of Management Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. Primary brain tumors range from

Full access

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

Background Bone metastases are common in patients presenting with metastatic non–small cell lung cancer (NSCLC) and are often treated with palliative radiation therapy. 1 There exists wide practice variability in palliative treatment

Full access

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

Background Bone metastases are common in patients presenting with metastatic non–small cell lung cancer (NSCLC) and are often treated with palliative radiation therapy. 1 There exists wide practice variability in palliative treatment

Full access

David S. Ettinger, Gregory J. Riely, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

, treatment, and management of these mediastinal tumors. Mediastinal Masses Masses in the anterior mediastinum can be neoplasms (eg, thymomas, lymphomas, thymic carcinomas, thymic carcinoids, thymolipomas, germ cell tumors, lung metastases) or

Full access

Luxi Chen, John Davelaar, Srinivas Gaddam, Kambiz Kosari, Nicholas Nissen, George Chaux, Christopher Lee, Eric Vail, Andrew Hendifar, Jun Gong, Karen Reckamp, and Arsen Osipov

metastases from lung primaries account for approximately 9% to 14.7% of all pancreatic metastases, representing <0.3% of all pancreatic malignancies. 6 , 7 Pancreatic secondaries are rarely diagnosed simultaneously with the primary tumor because they are

Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

subcutaneously administered monoclonal antibody. They are indicated in the treatment and prevention of bone metastases and skeletal-related events and of osteoporosis in patients receiving hormone therapy. 1 – 6 These agents are also routinely used for

Full access

Elizabeth G. Grubbs and Douglas B. Evans

cervical lymph node metastases from papillary carcinoma of the thyroid . Br J Surg 2001 ; 88 : 1241 – 1244 . 21. Machens A Hinze R Thomusch O Dralle H . Pattern of nodal metastasis for primary and reoperative thyroid cancer . World J Surg

Full access

Jeffrey A. Norton, Tony D. Fang, and Robert T. Jensen

arterial chemoembolization in the management of advanced digestive endocrine tumors . Digestion 2000 ; 62 : 79 – 83 . 25. Ruszniewski P Rougier P Roche A . Hepatic arterial chemoembolization in patients with liver metastases of endocrine

Full access

Karen L. Reckamp

in patients with and without brain metastases, and has less toxicity than either the first- or second-generation EGFR TKIs. Virtually all patients who experience response to frontline EGFR TKI therapy develop resistance. The most common mechanism of

Full access

Joe Y. Chang and Vivek Verma

not. 3 , 5 In addition, brain metastases have historically been associated with a poorer prognosis and have been highly underrepresented in existing randomized trials ( Table 1 ); whether these patients receive the same benefit from local therapy as